SCHEMBL30765971

SCHEMBL30765971

CSc1ncc(N)c(=O)n1CC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.38
ADORA2B P29275 1/20 0.37
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
GAA P10253 1/20 0.34
ELANE P08246 4/20 0.33
CTRC Q99895 2/20 0.33
CMA1 P23946 1/20 0.33
APEX1 P27695 1/20 0.33
TP53 P04637 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765704 0.84 KDM4E (0.43) POLBKDM4EALDH1A1TP53
SCHEMBL5565965 0.83 POLB (0.38) POLBADORA2BKDM4EALDH1A1HPGD
SCHEMBL6800734 0.80 GAA (0.40) ADORA2BKDM4EALDH1A1HPGDGAA
SCHEMBL6804071 0.72 ELANE (0.50) POLBALDH1A1HPGDELANECTRC
SCHEMBL6239360 0.72 CMA1 (0.53) KDM4EELANECTRCCMA1
SCHEMBL6804111 0.71 CMA1 (0.53) KDM4EELANECTRCCMA1
Hydrochloric Acid SCHEMBL6805327 0.71 CMA1 (0.53) KDM4EELANECTRCCMA1
SCHEMBL6801619 0.71 TSHR (0.45) KDM4EALDH1A1HPGDELANECTRC
SCHEMBL6802585 0.70 ELANE (0.40) ELANECTRCCMA1
SCHEMBL6805368 0.69 ELANE (0.53) ELANECTRCCMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed